Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells

Bo Yin, Yang Yang, Zhiqiang Zhao, Yu Zeng, Steven M. Mooney, Ming Li, Xuewen Xu, Yongsheng Song, Bin Wu, Zhibo Yang

Research output: Contribution to journalArticle


The presence of arachidonate 12-lipoxygenase (12-LOX) potentiates prostate cancer (PCa) progression and therefore may be a good therapeutic target and/or a potential diagnostic predictor for PCa. In this study, we examined the expression of 12-LOX in PCa stem cells (PCa SCs) to test if it can serve as a unique marker and therapeutic target for PCa SCs. To this end, we isolated the cancer stem cell-like side population (SP) cells from the human PCa cell line DU-145 by a flow cytometry-based SP technique. The isolated DU-145 SP cells comprised a small population of the DU-145 cells. The SP cells had an up-regulation of ATP-binding cassette sub-family G member 2 (ABCG2) which enables these cells to efflux vital dyes and chemotherapeutic drugs. Furthermore, we detected a strong up-regulation of 12-LOX in these DU-145 SP cells compared to the parental DU-145 cells by RT-PCR and Western blot approaches. We also detected 12-LOX overexpression in PCa SCs in human PCa tissue samples by paraffin-section based immunofluorescent 4-channel confocal microscopy. However, no 12-LOX was detected in normal prostate epithelial SCs in normal prostate tissue samples. These multiple lines of evidence support the possibility that 12-LOX may serve as a unique marker and therapeutic target for PCa SCs.

Original languageEnglish (US)
Pages (from-to)1041-1046
Number of pages6
JournalInternational journal of oncology
Issue number4
StatePublished - Apr 1 2011
Externally publishedYes

Cite this